Clinical Trial: Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07915505) titled 'Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis' on Sept. 02, 2022.

Brief Summary: Cytomegalovirus (CMV) is a major cause of morbidity in hematopoietic stem cell transplant recipients, with both direct effects, including CMV disease, and indirect effects, such as graft-versus-host disease (GVHD) and increased immunosuppression.

Virological monitoring and preemptive treatment with ganciclovir have reduced the incidence of CMV disease from approximately 30% to 2-6%, but have not eliminated the indirect morbidity associated with viral replication. Letermovir, a non-hematotoxic antiviral agent ...